Lanthanum: A safe phosphate binder

Seminars in Dialysis

Volumn 19, Issue 3, 2006, Pages 195-199

  Persy, Veerle P ^a   Behets, Geert J ^a   Bervoets, An R ^a   De Broe, Marc E ^a   D'Haese, Patrick C ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LANTHANUM; LANTHANUM CARBONATE; PHOSPHATE BINDING PROTEIN;

ANIMAL; BIOAVAILABILITY; BLOOD; BONE; BRAIN; CALCINOSIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; LIVER; LIVER CELL; METABOLISM; REVIEW;

ANIMALS; BIOLOGICAL AVAILABILITY; BONE AND BONES; BRAIN; CALCINOSIS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HEPATOCYTES; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; LIVER; PHOSPHATE-BINDING PROTEINS;

EID: 33646689092     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2006.00169.x     Document Type: Review

References (32)

1. Silver J, Kilav R, Naveh-Many T: Mechanisms of secondary hyperparathyroidism. Am J Physiol Ren Physiol 283: F367 F376, 2002
2. Silver J: Pathogenesis of parathyroid dysfunction in end-stage renal disease. Adv Ren Replace Ther 9: 159 167, 2002
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607 617, 1998
4. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520 528, 2005
5. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 2131 2138, 2001
6. Prie D, Beck L, Urena P, Friedlander G: Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens 14: 318 324, 2005
7. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478 1483, 2000
8. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731 1740, 2003
9. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK: Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19: 1489 1496, 2004
10. Giachelli CM: Vascular calcification. in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14: S300 S304, 2003
11. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10 E17, 2000
12. Giachelli CM: Ectopic calcification: new concepts in cellular regulation. Z Kardiol 90 suppl 3 31 37, 2001
13. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX: Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63: 1003 1011, 2003
14. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638 647, 2002
15. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245 252, 2002
16. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815 1824, 2005
17. Braunlin W, Zhorov E, Guo A, Apruzzese W, Xu Q, Hook P, Smisek DL, Mandeville WH, Holmes-Farley SR: Bile acid binding to sevelamer HCl. Kidney Int 62: 611 619, 2002
18. Brezina B, Qunibi WY, Nolan CR: Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int Suppl 90: S39 S45, 2004
19. Damment SJP, Gill M: The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol), a new non-aluminum, non-calcium phosphate binder [abstract]. J Am Soc Nephrol 14: 204A, 2003
20. Jouhanneau P, Raisbeck GM, Yiou F, Lacour B, Banide H, Drueke TB: Gastrointestinal absorption, tissue retention, and urinary excretion of dietary aluminum in rats determined by using 26Al. Clin Chem 43: 1023 1028, 1997
21. Coburn JW, Mischel MG, Goodman WG, Salusky IB: Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 17: 708 711, 1991
22. Damment SJP, Greaves P, Downes N: The toxicology of lanthanum carbonate (Fosrenol), a new non-aluminum, non-calcium phosphate binder [abstract]. J Am Soc Nephrol 14: 204A, 2003
23. Behets GJ, Dams G, Vercauteren SR, Damment SJ, Bouillon R, De Broe ME, D'Haese PC: Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 15: 2219 2228, 2004
24. Damment SJ, Shen V: Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats. Clin Nephrol 63: 127 137, 2005
25. Behets GJ, Gritters M, Dams G, De Broe ME, D'Haese PC: Effects of efficient phosphate binding on bone in chronic renal failure rats. Ren Fail 27: 475 484, 2005
26. Rodriguez M, Felsenfeld AJ, Llach F: Aluminum administration in the rat separately affects the osteoblast and bone mineralization. J Bone Miner Res 5: 59 67, 1990
27. Behets GJ, Bervoets AJ, Dams G, Damment SJ, De Broe ME, D'Haese PC: Effects of lanthanum and strontium on osteoblasts in chronic renal failure rats [abstract]. J Am Soc Nephrol 14: 898A, 2003
28. Behets GJ, Verberckmoes SC, Oste L, Bervoets AR, Salome M, Cox AG, Denton J, De Broe ME, D'Haese PC: Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 67: 1830 1836, 2005
29. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 85: S73 S78, 2003
30. Yang Z, Schryvers D, Roels F, D'Haese PC, De Broe ME: Demonstration of La in liver cells by EDX, EELS and HRTEM. J Microsc submitted
31. D'Haese PC, Yang Z, Schryvers D, Roels F, Behets GJ, Verberckmoes SC, Bervoets AJ, Dauwe S, Salome M, De Broe ME: Lanthanum is localized (sub)cellularly in lysosomes of the liver [abstract]. J Am Soc Nephrol 16: 737A, 2005
32. Hutchison A: Analysis of liver function and hepatobiliary adverse event data from 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate [abstract]. Nephrol Dial Transplant 20 suppl 5 v93, 2005